MEDICURE ANNOUNCES RESULTS OF 2022 AGM
Monday, June 20, 2022
Our vision is to become a leading pharmaceutical company within the U.S., offering a growing portfolio of products that improve patients' lives.
At Medicure, we are focused on improving the health of patients by offering a growing portfolio of products and services and ensuring all patients get access to care they need.
At Medicure, our mission is to serve patients by delivering safe and efficacious life-changing medicines
Medicure Inc. announced first quarter results for the period ended 31 March 2022 on Tuesday 31 May.
Medicure Inc.– via Marley Drug, creates a direct-to-consumer e-commerce pharmacy solution. The service is available in all 50 states and can fulfill a formulary of over 100 prescription medications.
Partnership will integrate Marley Drug as the sole mail-order pharmacy for the RxSpark platform allowing consumers using the platform to receive medication directly to their door.
Medicure has filed with the FDA an IND for the use of MC-1 as a novel treatment for seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.
At Medicure, we are focused on improving the heart health of patients by delivering safe and efficacious cardiovascular medicines and ensuring all patients get access to therapy.
Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial in Patients with Aneurysmal Subarachnoid Hemorrhage
Copyright © 2022 Medicure Inc. All Rights Reserved. | Privacy Statement